The market yawns. An investment opportunity

Here is a summary of an article by Keith Williams in Seeking Alpha.

Summary
-Merck initiates Phase 1 cognitive dysfunction in Alzheimer’s trial on Bionomics candidate with a $10M milestone payment.
-Validation of Bionomics ionX screening and MultiCore chemistry platforms.
-Deepening relationship with Merck which owns 4.5% of the company.
-Merck program adds to Bionomics in house BNC210 program on anxiety, depression and PSTD (Post-Traumatic Stress Disorder).
-The Australian market yawned; investment opportunity.

His last point is worth noting (for those who haven't been inclined to buy shares or those who think they should buy more). IMO, I agree that it is an investment opportunity but DYOR. GLTA